Semaglutide's label now spans six approved uses
Semaglutide now carries six separate FDA-approved uses across Ozempic, Rybelsus and Wegovy, but each brand and dosage form covers only part of that list.
Semaglutide, the molecule in Ozempic, Rybelsus and Wegovy, now has six distinct FDA-approved uses spread across its brands and dosage forms: type 2 diabetes, cardiovascular risk reduction in type 2 diabetes, chronic kidney disease in type 2 diabetes, chronic weight management, cardiovascular risk reduction in obesity or overweight, and noncirrhotic MASH with moderate to advanced liver fibrosis [1][2].
No single product covers all six. The uses are split between the diabetes brands and the obesity brand, and even within a brand the injection and the pill are not interchangeable on the label.
How the six uses got there
Ozempic injection was first approved December 5, 2017 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes [2]. It added cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease on January 16, 2020 [2]. On January 28, 2025, it added a third indication: reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [2]. Novo Nordisk described that as the only GLP-1 receptor agonist approval of its kind at the time [2].
Wegovy injection was approved June 4, 2021 for weight management in adults with obesity [1], extended to adolescents aged 12 and older on December 23, 2022 [1], and on March 8, 2024 became approved to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight [1]. On August 15, 2025, Wegovy received accelerated approval for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, consistent with stages F2 to F3, in adults [1].
The MASH indication comes with a caveat. It was granted under accelerated approval based on improvement in MASH and fibrosis, and continued approval "may be contingent upon the verification and description of clinical benefit in a confirmatory trial" [1].
The oral versions cover less
The pills carry narrower labels. Rybelsus, first approved September 20, 2019, is indicated for type 2 diabetes and for reducing major adverse cardiovascular events in adults with type 2 diabetes at high risk [2]. A newer oral formulation approved December 9, 2024 was rebranded as Ozempic tablets on January 30, 2026, with the same two diabetes-related uses [2].
Wegovy tablets, approved December 22, 2025 in 1.5 mg, 4 mg, 9 mg and 25 mg strengths, are indicated for weight reduction and maintenance and for cardiovascular risk reduction in obesity or overweight — but not for MASH [1][2]. A higher-dose Wegovy HD 7.2 mg injection was approved March 19, 2026 [1].
Why it matters for patients
A wider label is not the same as wider access. Insurance coverage generally tracks the specific indication on the specific product, so someone with MASH and someone with chronic kidney disease may need different semaglutide products even though the active drug is the same. The labeling also states that using Wegovy injection or tablets together with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended [1].
The safety profile is unchanged by the added indications. All semaglutide products carry a boxed warning for thyroid C-cell tumors [1][2]. Warnings and precautions include acute pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in type 2 diabetes, increased heart rate, suicidal behavior and ideation, and pulmonary aspiration during general anesthesia or deep sedation [1]. Nausea, diarrhea, vomiting, constipation and abdominal pain are the most common side effects [1][2].
These two sources do not contain a head-to-head comparison of semaglutide's label with tirzepatide (Mounjaro/Zepbound) or orforglipron (Foundayo), so the claim that no other GLP-1 matches this range cannot be verified from them.
What happens next
A confirmatory trial is required to support continued approval of the MASH indication; a completion date is not given in these sources [1]. Novo Nordisk said Ozempic tablets would be available in the US in the second quarter of 2026 [2]. The company also announced a US list price reduction for Wegovy, Ozempic and Rybelsus on February 24, 2026 [1][2].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.